To learn more about our prospective biomarker study please click here.
Idylla™ ctEGFR Available Now! Click here for more information

October 2-5, 2018 | Boston, MA

World CDx 2018

Attend World CDx Boston to discover the very latest data proving their clinical utility in responder selection and outcome monitoring. Be at the pinnacle of crucial and candid conversation to discover why, how and when to adopt a CDx strategy.


Oct 2-5, 2018​

To be confirmed

Request A Demo

Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.

One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.